Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL (Cancer Immunology, Immunotherapy, (2021), 70, 12, (3701-3708), 10.1007/s00262-021-03008-0)

Sarah B. Reusing, Dan A. Vallera, Angela R. Manser, Titus Watrin, Sanil Bhatia, Martin Felices, Jeffrey S. Miller, Markus Uhrberg, Florian Babor

Research output: Contribution to journalComment/debatepeer-review

Abstract

The original version of this article unfortunately contained a mistake. Author name Titus Watrin was incorrectly written as Titus Vatrin.

Original languageEnglish (US)
Pages (from-to)3709
Number of pages1
JournalCancer Immunology, Immunotherapy
Volume70
Issue number12
Early online dateSep 7 2021
DOIs
StatePublished - Dec 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2021, The Author(s).

PubMed: MeSH publication types

  • Published Erratum

Fingerprint

Dive into the research topics of 'Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL (Cancer Immunology, Immunotherapy, (2021), 70, 12, (3701-3708), 10.1007/s00262-021-03008-0)'. Together they form a unique fingerprint.

Cite this